tert-butyl (2R)-2-[5-[4-[7-[3-[[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]amino]phenyl]spiro[1,3-dihydroindene-2,1'-cyclopentane]-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: tert-butyl (2R)-2-[5-[4-[7-[3-[[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]amino]phenyl]spiro[1,3-dihydroindene-2,1'-cyclopentane]-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
• 化学式: C₄₇H₅₇N₅O₅
• 分子量: 772.0
• InChiKey: AGDMONGNWBENSQ-PVXQIPPMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  57
• 可旋转键数：
  10
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Zhang Jiancun

  公开号：US20140147412A1

  公开（公告）日：2014-05-29

  Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.
• US9303061B2
  申请人：——

  公开号：US9303061B2

  公开（公告）日：2016-04-05